close
Generic drugs

Potential Medicare Part D savings on generic drugs from pharmaceutical company Mark Cuban Cost Plus

Memberships:

Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

Financial aid: By Arnold Ventures (Drs Kesselheim and Rome).

Disclosures: The disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-0756.

Reproducible research statement: Study protocol: Available from Dr Lalani (email, [email protected]Harvard.educated). Statistics code: Not applicable. Database: Available at https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug and https:// costplusdrugs.com/medications/. This study was not submitted for institutional review board review because it used publicly unidentifiable data that does not constitute research on human subjects (45 CFR 46.102).

Corresponding author: Hussain S. Lalani, MD, MPH, 1620 Tremont Street, Suite 3030, Boston, MA 02120; E-mail, [email protected]Harvard.educated.

Correction: This article was corrected on July 8, 2022 to reflect a revised analysis that corrected mismatches on drug formulation and strength. Text, table and figure data have been updated.

This article was published on Annals.org on June 21, 2022.

Joan J. Dean

The author Joan J. Dean